Novel approach could offer hope in treatment of inflammatory conditions

The team, led by researchers at Imperial College London, Queen Mary University of London and Ergon Pharmaceuticals, believes the approach could offer new hope in the treatment of inflammatory conditions like arthritis, autoimmune diseases, and sepsis.

In a study published this week in the journal Nature Communications, they explain how blocking a single enzyme-enabled them to reprogram macrophages – the immune cells which are activated in inflammatory conditions – to calm their activity and reduce inflammation in rats and mice with human-like disease.

Read more